AZN logo

AstraZeneca PLC

AZN
Healthcare|Drug Manufacturers - General|GB
$186.43
-0.42 (-0.22%)
DCF Value
$500.17
Graham Number
$72.85
Cash / Share
$5.23

Financials

Financial Snapshot

Market Cap
$289.13B
Enterprise Value
$314.95B
Revenue (TTM)
$62.17B
Net Income (TTM)
$10.99B
Cash & Investments
$8.15B
Net Cash
-$25.98B
Free Cash Flow (TTM)
$9.32B
Operating CF (TTM)
$13.33B
Debt/Equity
0.66

Cash Runway & Burn Rate

Company is cash-flow positive.

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$5.90B$4.55B$5.68B$6.22B$7.99B$6.40B$6.24B$5.86B$5.53B$5.74B$8.15B
Operating Cash Flow
$4.14B$3.58B$2.62B$2.97B$4.80B$5.96B$9.81B$10.35B$11.86B$14.57B$13.33B
Free Cash Flow
$1.83B$1.96B$1.25B$509.0M$2.19B$3.76B$7.24B$6.57B$7.28B$8.67B$9.32B
Capital Expenditure
-$2.31B-$1.62B-$1.37B-$2.46B-$2.61B-$2.20B-$2.57B-$3.78B-$4.59B-$5.91B-$4.01B
Financing Cash Flow
-$1.32B-$2.94B-$2.04B-$1.76B-$2.20B$3.65B-$6.82B-$6.57B-$4.00B-$7.54B-$5.39B

R&D Spending

R&D (TTM)
$15.01B
R&D Intensity
24.1%
R&D Growth vs Prior
+5.4%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$23.00B$22.46B$22.09B$24.38B$26.62B$37.42B$44.35B$45.81B$54.07B$58.74B$62.17B
R&D Expense
$5.89B$5.76B$5.93B$6.06B$5.99B$9.74B$9.76B$10.94B$13.58B$14.23B$15.01B
R&D % of Revenue
25.6%25.6%26.9%24.8%22.5%26.0%22.0%23.9%25.1%24.2%24.1%
SG&A
$9.74B$10.54B$10.98B$11.98B$11.90B$15.59B$17.98B$18.22B$20.22B$20.51B$21.76B

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$23.00B$22.46B$22.09B$24.38B$26.62B$37.42B$44.35B$45.81B$54.07B$58.74B$62.17B
Cost of Revenue
$4.13B$4.32B$4.94B$4.92B$5.30B$12.44B$12.39B$8.27B$10.21B$10.63B$12.38B
Gross Profit
$18.88B$18.15B$17.15B$19.46B$21.32B$24.98B$31.96B$37.54B$43.87B$48.11B$49.79B
R&D
$5.89B$5.76B$5.93B$6.06B$5.99B$9.74B$9.76B$10.94B$13.58B$14.23B$15.01B
SG&A
$9.74B$10.54B$10.98B$11.98B$11.90B$15.59B$17.98B$18.22B$20.22B$20.51B$21.76B
Operating Income
$4.90B$3.68B$3.39B$2.92B$5.16B$1.06B$3.76B$8.19B$10.00B$13.74B$14.71B
Interest Expense
$1.37B$1.36B$1.37B$1.40B$1.27B$1.28B$1.33B$1.59B$1.68B$1.69B$1.77B
Pretax Income
$3.55B$2.23B$1.99B$1.55B$3.92B-$265.0M$2.50B$6.90B$8.69B$12.40B$13.25B
Net Income
$3.50B$3.00B$2.15B$1.33B$3.20B$112.0M$3.29B$5.96B$7.04B$10.26B$10.99B
EPS (Diluted)
2.762.371.701.032.440.082.113.814.506.547.01
EBITDA
$7.28B$6.62B$7.11B$6.71B$8.08B$5.11B$9.09B$13.42B$15.44B$19.83B$21.37B
Shares Out. (M)
1266.001267.001267.001301.001313.001427.001560.001562.001563.001562.001560.00

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$5.02B$3.32B$4.83B$5.37B$7.83B$6.33B$6.17B$5.84B$5.49B$5.71B$7.92B
Short-Term Investments
$884.0M$1.23B$849.0M$849.0M$160.0M$69.0M$77.0M$20.0M$37.0M$30.0M$229.6M
Total Current Assets
$13.26B$13.15B$15.59B$15.56B$19.54B$26.24B$22.59B$25.05B$25.83B$28.72B$31.39B
Total Assets
$62.53B$63.35B$60.65B$61.38B$66.73B$105.36B$96.48B$101.12B$104.03B$114.07B$119.71B
Total Current Liabilities
$15.26B$16.38B$16.29B$18.12B$20.31B$22.59B$26.29B$30.54B$27.87B$30.62B$31.21B
Long-Term Debt
$16.51B$17.39B$19.20B$15.73B$17.50B$28.13B$22.96B$22.36B$26.51B$24.71B$26.42B
Total Liabilities
$45.86B$46.71B$46.61B$46.78B$51.09B$66.08B$59.42B$61.95B$63.16B$65.36B$67.99B
Stockholders' Equity
$14.85B$14.96B$12.47B$13.13B$15.62B$39.27B$37.04B$39.14B$40.79B$48.67B$51.64B
Retained Earnings
$8.14B$8.22B$5.68B$2.81B$5.30B$1.71B-$574.0M$4.52B$3.16B$10.97B$14.04B

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
$4.14B$3.58B$2.62B$2.97B$4.80B$5.96B$9.81B$10.35B$11.86B$14.57B$13.33B
Capital Expenditure
-$2.31B-$1.62B-$1.37B-$2.46B-$2.61B-$2.20B-$2.57B-$3.78B-$4.59B-$5.91B-$4.01B
Free Cash Flow
$1.83B$1.96B$1.25B$509.0M$2.19B$3.76B$7.24B$6.57B$7.28B$8.67B$9.32B
Investing Cash Flow
-$3.97B-$2.33B$963.0M-$657.0M-$285.0M-$11.06B-$2.96B-$4.06B-$7.98B-$6.81B-$8.16B
Financing Cash Flow
-$1.32B-$2.94B-$2.04B-$1.76B-$2.20B$3.65B-$6.82B-$6.57B-$4.00B-$7.54B-$5.39B
Issuance of Stock
$47.0M$43.0M$34.0M$3.52B$30.0M$29.0M$29.0M$33.0M-$43.0M-$481.0M-$568.7M
Repurchase of Stock
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00-$348.8M
Net Debt Issuance
$2.48B$224.0M$1.47B-$1.19B$1.65B$7.89B-$1.20B-$965.0M$1.81B-$1.65B$793.3M
Stock Based Comp.
$0.00$0.00$0.00$259.0M$277.0M$615.0M$619.0M$579.0M$0.00$0.00$0.00
Net Change in Cash
-$1.13B-$1.75B$1.50B$552.0M$2.32B-$1.51B-$55.0M-$346.0M-$208.0M$269.0M-$251.4M

Dilution Tracker

Shares Outstanding
1551M
5-Year Share Growth
+19.0%
Stock Issuance (TTM)
-$568.7M
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
1266.001267.001267.001301.001313.001427.001560.001562.001563.001562.001560.00
Change vs Prior %
—0.1%0.0%2.7%0.9%8.7%9.3%0.1%0.1%-0.1%-0.1%
Stock Issuance
$47.0M$43.0M$34.0M$3.52B$30.0M$29.0M$29.0M$33.0M-$43.0M-$481.0M-$568.7M
Stock Repurchase
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00-$348.8M
Stock Based Comp.
$0.00$0.00$0.00$259.0M$277.0M$615.0M$619.0M$579.0M$0.00$0.00$0.00

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
82.1%80.8%77.7%79.8%80.1%66.8%72.1%82.0%81.1%81.9%80.1%
Operating Margin %
21.3%16.4%15.3%12.0%19.4%2.8%8.5%17.9%18.5%23.4%23.7%
Net Margin %
15.2%13.4%9.8%5.5%12.0%0.3%7.4%13.0%13.0%17.5%17.7%
EBITDA Margin %
31.6%29.5%32.2%27.5%30.4%13.7%20.5%29.3%28.6%33.8%34.4%
FCF Margin %
8.0%8.7%5.6%2.1%8.2%10.1%16.3%14.3%13.5%14.8%15.0%
ROE %
23.6%20.1%17.3%10.2%20.5%0.3%8.9%15.2%17.2%21.1%22.3%
ROA %
5.6%4.7%3.6%2.2%4.8%0.1%3.4%5.9%6.8%9.0%9.3%
ROIC %
9.5%7.5%7.3%5.1%8.5%-0.5%5.0%9.3%10.3%13.0%13.1%
R&D / Revenue %
25.6%25.6%26.9%24.8%22.5%26.0%22.0%23.9%25.1%24.2%24.1%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
-6.9%-2.3%-1.7%10.4%9.2%40.6%18.5%3.3%18.0%8.6%
Gross Profit
-5.9%-3.9%-5.5%13.5%9.5%17.2%27.9%17.5%16.8%9.7%
Operating Income
19.2%-25.0%-7.9%-13.7%76.5%-79.5%255.8%118.1%22.1%37.4%
Net Income
23.9%-14.2%-28.2%-38.1%139.4%-96.5%2835.7%81.1%18.1%45.8%
EPS (Diluted)
23.8%-14.1%-28.3%-39.4%136.9%-96.7%2537.5%80.6%18.1%45.3%
Operating Cash Flow
24.7%-13.7%-26.8%13.4%61.6%24.3%64.5%5.5%14.7%22.9%
Free Cash Flow
241.6%6.9%-36.3%-59.2%330.8%71.6%92.3%-9.3%10.8%19.2%
R&D Expense
-1.8%-2.3%3.0%2.1%-1.1%62.5%0.3%12.0%24.2%4.8%
SG&A Expense
-15.4%8.3%4.2%9.1%-0.7%31.1%15.4%1.3%11.0%1.4%
Total Assets
4.0%1.3%-4.3%1.2%8.7%57.9%-8.4%4.8%2.9%9.6%
Book Value / Share
-10.0%-0.2%-15.7%1.2%6.2%132.4%-13.6%4.7%5.2%19.2%
Debt
11.7%5.9%7.3%-4.6%11.8%50.6%-5.0%-1.8%5.2%-1.4%
Diluted Shares
0.1%0.1%0.0%2.7%0.9%8.7%9.3%0.1%0.1%-0.1%

Valuation

P/E (TTM)26.16
10Y Low / Med / High19.45 / 41.39 / 1448.13
P/S4.63
10Y Low / Med / High2.96 / 4.58 / 5.39
P/B5.62
10Y Low / Med / High4.18 / 5.69 / 10.01
EV/EBITDA14.75
10Y Low / Med / High10.99 / 17.34 / 36.89
EV/Revenue5.05
10Y Low / Med / High3.48 / 5.04 / 5.92
P/FCF31.74
10Y Low / Med / High27.70 / 43.66 / 258.16

Intrinsic Value Models (per share)

DCF Value
$500.17
Graham Number
$72.85
Cash / Share
$5.23
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
19.4529.2844.6898.0641.391448.1364.2535.2928.6326.5926.16
P/S Ratio
2.963.914.365.394.984.394.754.583.734.634.63
P/B Ratio
4.595.877.7210.018.484.185.695.374.945.595.62
EV/EBITDA
10.9915.4515.5421.4917.9436.8925.7417.3414.6514.9314.75
EV/Revenue
3.484.565.005.925.455.045.275.084.185.045.05

Analyst Estimates & Quality

Altman Z-Score
3.65
Safe
Piotroski F-Score
7
Strong

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$62.80B$66.92B$71.07B
Net Income$15.85B$17.66B$19.65B
EPS$10.26$11.34$12.61
# Analysts (EPS)7813

Dividends

Dividend/Share (TTM)
$3.20
Dividend Yield
1.72%
Frequency
Semi-Annual

Recent Payments

Ex-DatePay DateAmountFrequency
Aug 7, 2026Sep 8, 2026$1.06Semi-Annual
Feb 20, 2026Mar 23, 2026$2.17Semi-Annual
Aug 8, 2025Sep 8, 2025$0.52Semi-Annual
Feb 21, 2025Mar 24, 2025$1.05Semi-Annual
Aug 9, 2024Sep 9, 2024$0.50Semi-Annual
Feb 22, 2024Mar 25, 2024$0.98Semi-Annual
Aug 10, 2023Sep 11, 2023$0.47Semi-Annual
Feb 23, 2023Mar 27, 2023$0.96Semi-Annual
Aug 11, 2022Sep 12, 2022$0.46Semi-Annual
Feb 24, 2022Mar 28, 2022$0.96Semi-Annual
Aug 12, 2021Sep 13, 2021$0.44Semi-Annual
Feb 25, 2021Mar 29, 2021$0.95Semi-Annual
Aug 13, 2020Sep 14, 2020$0.44Semi-Annual
Feb 27, 2020Mar 30, 2020$0.95Semi-Annual
Aug 8, 2019Sep 9, 2019$0.45Semi-Annual
Feb 28, 2019Mar 27, 2019$0.95Semi-Annual
Aug 9, 2018Sep 10, 2018$0.45Semi-Annual
Feb 15, 2018Mar 19, 2018$0.95Semi-Annual
Aug 9, 2017Sep 11, 2017$0.45Semi-Annual
Feb 15, 2017Mar 20, 2017$0.95Semi-Annual

Revenue Segments

By Product

Segment201920202021202220232025
Crestor$1.28B$1.18B$1.10B$1.05B$1.11B$1.22B
Arimidex$225.0M——$99.0M——
Atacand$221.0M—————
Brilinta$1.58B——$1.36B$1.32B$823.0M
Bydureon$549.0M——$280.0M$163.0M—
Byetta$110.0M—————
Calquence$164.0M——$2.06B$2.51B$3.52B
Cardiovascular And Metabolic Diseases Products$6.91B—————
Casodex$200.0M——$78.0M——
Daliresp Daxas$215.0M—————
Duaklir$77.0M—————
Farxiga$1.54B——$4.38B$5.96B$8.40B
Fasenra$704.0M——$1.40B$1.55B$1.98B
Faslodex$892.0M——$334.0M$297.0M—
Imfinzi$1.47B——$2.78B$4.24B$6.06B
Iressa$423.0M——$114.0M——
Losec Prilosec$263.0M—————
Lynparza$1.20B——$2.64B$2.81B$3.28B
Nexium$1.48B—$1.33B$1.28B$945.0M$816.0M
Oncology Products$8.67B—————
Onglyza$527.0M——$257.0M$227.0M—
Other Cardiovascular And Metabolic Diseases Products$271.0M—————
Other Diabetes$52.0M—————
Other Oncology Products$94.0M—————
Other Products Others$306.0M—————
Other Products$2.60B—————
Other Respiratory Products$390.0M—————
Pulmicort$1.47B——$645.0M$713.0M$518.0M
Respiratory Products$5.39B—————
Seloken Toprol Xl$760.0M—————
Seroquel Xr Ir$191.0M—————
Symbicort$2.50B——$2.54B$2.36B$2.88B
Tagrisso$3.19B——$5.44B$5.80B$7.25B
Zoladex$813.0M$888.0M$948.0M$927.0M$952.0M$1.11B
Bevespi$42.0M——$58.0M$58.0M—
Lokelma$14.0M——$289.0M$412.0M$698.0M
Synagis$358.0M——$578.0M$546.0M$292.0M
Breztri$2.0M——$398.0M$677.0M$1.20B
Lynparza And Koselugo—$460.0M————
Other Collaboration Revenue—$46.0M————
Royal Revenue—$62.0M————
Lynparza/Koselugo——$400.0M———
Other Ongoing Collaboration Revenue——$64.0M———
Profit share revenue from product sales by collaboration partners——$200.0M———
Royal income——$138.0M———
Enhertu——$17.0M$79.0M$1.02B$1.80B
Roxadustat——$174.0M$197.0M$271.0M$274.0M
Collaboration Revenue——$12.0M———
BioPharmaceuticals: total Respiratory & Immunology———$5.76B——
CVRM———$9.19B$10.59B$12.76B
Daliresp/Daxas———$189.0M$54.0M—
FluMist———$175.0M$216.0M$272.0M
Kanuma———$160.0M$171.0M—
Koselugo———$208.0M$331.0M$662.0M
Oncology, Others———$44.0M$224.0M$425.0M
Ophatys———$33.0M——
Other, Others———$340.0M$231.0M$156.0M
Rare Disease———$7.05B$7.76B$9.13B
Respiratory, Others———$421.0M——
Seloken/Toprol-XL———$862.0M$640.0M—
Soliris———$3.76B$3.15B$1.84B
Strensiq———$958.0M$1.15B$1.68B
Total Oncology———$14.63B$17.14B$23.70B
Total Other medicines———$1.63B$1.18B$972.0M
Ultomiris.———$1.97B$2.96B—
Vaxzevria———$1.80B$12.0M—
Andexxa———$150.0M$182.0M—
Saphnelo———$116.0M$280.0M$686.0M
Ultomiris—————$4.72B

By Geography

Segment2025
Asia, Africa And Australasia$13.37B
Europe excluding the United Kingdom$13.46B
The Americas$27.56B
UNITED KINGDOM$4.36B